SEC Form 4 · accession 0001104659-18-019944
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Y Chan
Officer — See Remarks
Period of report
Mar 15, 2018
Accepted (ET)
Mar 26, 2018 · 6:07 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Mar 15, 2018 | A | 8,600 | $0.00 | A | 22,384 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3,F4 | $4.52 | Mar 15, 2018 | A | 40,000 | A | — | Mar 15, 2028 | Common Shares | 40,000 | 40,000 | D |
Explanation of responses
- F1These shares are issuable pursuant to a grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- F2The restricted stock units vest in three equal annual installments beginning March 15, 2019.
- F3Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F4This stock option will vest and become exercisable in three equal annual installments beginning March 15, 2019.
Remarks
President and Chief Accounting Officer of Aegerion Pharmaceuticals, Inc.